AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Nasdaq (NDAQ) rose 0.17% on July 30, 2025, with a trading volume of $310 million, ranking 396th in market activity. The stock reached a 52-week high earlier in the week, driven by analyst upgrades and institutional investment shifts. Recent analyst reports highlighted improved sentiment, with
and raising price targets to $115 and $108, respectively, while and maintained "buy" ratings. Institutional ownership increased in Q2, with entities like Quotient Wealth Partners and Kanawha Capital Management expanding their stakes.The company reported Q2 earnings of $0.85 per share, exceeding estimates by $0.07, with revenue rising 12.7% year-over-year to $1.31 billion. Strategic business units, including Verafin and AxiomSL, continue to drive growth in financial technology and compliance solutions. Insider activity saw reduced holdings from executives, though institutional investors collectively own 72.47% of the stock. A dividend of $0.27 per share is scheduled for September 26, reflecting a 1.13% yield.
Technical indicators suggest a bullish outlook, with the stock trading above both 50-day and 200-day moving averages. Analysts noted potential resistance at $100.19 and support near $93.50. Despite recent gains, the stock faces medium risk due to average daily volatility of 2.25% and a beta of 1.01. A double-bottom formation confirmed on July 23 further supports a positive near-term bias.
A backtested strategy of purchasing the top 500 most actively traded stocks daily and holding for one day generated a 166.71% return from 2022 to 2025. This outperformed the benchmark by 137.53% with a compound annual growth rate (CAGR) of 31.89% and a Sharpe ratio of 1.14, underscoring its strong risk-adjusted performance over the period.
Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.

Dec.26 2025

Dec.26 2025

Dec.25 2025

Dec.24 2025

Dec.24 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet